WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Transplant Product Efficacy Framework_EGP, Glomerular Filtration Rate (GFR) can be measured by cold-iothalamate method, Decreased GFR is associated with Cardiovascular (CV) risk, urine output is measured as decreased, Biopsy Indication of Rejection can be confirmed as BCAR (Biopsy Confirmed Acute Rejection), defined time points between 3 months, Concepts (e.g. Graft survival) are denoted by solid round-edged rectangle, BCAR (Biopsy Confirmed Acute Rejection) is assessed by Biopsy, Flow rates can be thresholded at 60 mL/min, Date of Graft Loss is earliest occurance of DeathDueToRejection, defined time point including 6 months, Graft Loss is the inverse of Graft Survival, Renal function/ Impairment leads to Long Term Dialysis, Study treatments include Belatacept, Clinically suspected Acute Rejection can be defined by graft tenderness, Banff grade can be IIA, Glomerular Filtration Rate (GFR) is measured as Elevated GFR, Therapeutic Efficacy Point is the intersection of Physiolgoical Process, Treated BPAR episode is assessed by Biopsy, Biopsy Indication of Rejection is assessed by Pathologist, Main concepts (e.g. Death, Graft Loss) are denoted by Larger bold font with thicker outline